Canine atopic dermatitis (CAD) is a chronic, allergic inflammatory skin disease affecting approximately 10 percent of dogs, causing persistent pruritis and secondary skin infection that significantly impairs welfare.
Canine atopic dermatitis causes chronic welfare suffering through persistent pruritis — the constant urge to scratch, lick, and chew affected areas disrupts sleep, prevents normal activity, and causes significant psychological distress. Dogs with severe atopy may scratch continuously, causing skin self-trauma with bleeding, pain, and secondary infection that adds to the welfare burden. The modern generation of anti-pruritic treatments (oclacitinib and lokivetmab) has transformed welfare outcomes — dogs experience rapid, dramatic reduction in pruritis that visibly improves their quality of life within days of treatment. Early treatment initiation rather than waiting for secondary infection prevents the compounded welfare harm of infection layered on top of allergic itch.